TherapeuticsMD to offer Bijuva
TherapeuticsMD on Wednesday announced the commercial availability of Bijuva (estradiol and progesterone capsules, 1 mg/100 mg) in the United States.
Bijuva is the first and only Food and Drug Administration-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
The product offers a proven balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical progesterone to reduce risks to the endometrium, the company said.
“We are excited to offer women, healthcare providers and pharmacists an answer to their desire for bio-identical hormone therapy,” TherapeuticsMD co-founder and director Brian Bernick said. “TherapeuticsMD is proud to offer Bijuva as an important new option to help manage the moderate to severe vasomotor symptoms experienced by up to 80% of menopausal women.”
As of April 19, 2019, three of the top ten commercial payers – Express Scripts, Anthem and Aetna – will be adjudicating Bijuva in the commercial health insurance channel for the majority of their formulary designs.
“The momentum we have seen early on with the payer community is encouraging and indicates recognition of the need for an FDA-approved combination bio-identical option,” TherapeuticsMD chief commercial officer Dawn Halkuff said. “I am proud to work for a company committed to advancing women’s health with new treatments for women and their healthcare providers.”
Bijuva is the first and only Food and Drug Administration-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral daily capsule for the treatment of moderate-to-severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.
The product offers a proven balance of bio-identical estradiol to reduce moderate to severe hot flashes combined with bio-identical progesterone to reduce risks to the endometrium, the company said.
“We are excited to offer women, healthcare providers and pharmacists an answer to their desire for bio-identical hormone therapy,” TherapeuticsMD co-founder and director Brian Bernick said. “TherapeuticsMD is proud to offer Bijuva as an important new option to help manage the moderate to severe vasomotor symptoms experienced by up to 80% of menopausal women.”
As of April 19, 2019, three of the top ten commercial payers – Express Scripts, Anthem and Aetna – will be adjudicating Bijuva in the commercial health insurance channel for the majority of their formulary designs.
“The momentum we have seen early on with the payer community is encouraging and indicates recognition of the need for an FDA-approved combination bio-identical option,” TherapeuticsMD chief commercial officer Dawn Halkuff said. “I am proud to work for a company committed to advancing women’s health with new treatments for women and their healthcare providers.”